News

Alex Shneider, Founder and CEO of CureLab Oncology, discusses DNA-based immunotherapies, inflammation-driven cancer biology, intelligent combination therapies, and the emerging science of reprogramming the tumour microenvironment.

Dr. Alex Shneider, CEO of Curelab Oncology and the developer of Elenagen joins eHealth Radio and the Health News and Cancer Information Channels to discuss this breakthrough.

Dr. Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and Director of Oncology at CureLab Oncology Inc., recently presented new clinical findings at the 27th Congress of the European Society of Gynaecological Oncology (ESGO 2026) in Copenhagen, highlighting a promising therapeutic advance for women with platinum-resistant ovarian cancer (PROC).

Base to Base biotech podcast 51: Ovarian cancer, blue crayfish, and stopping brittle bone disease

At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for platinum-resistant ovarian cancer (PROC); one of the most aggressive and treatment-refractory settings in gynecologic oncology.

Alexander Shneider, founder and CEO of CureLab Oncology, Inc. shared a post on LinkedIn: “We are honored to see our recent clinical data featured in EMJ Oncology. For patients with platinum‑resistant ovarian cancer – one of the most challenging diagnoses in oncology – these findings point toward what may become a meaningful paradigm shift.

Adding therapy to chemo shown to extend survival in small cancer trial

In this episode of the Talking Biotech podcast, host Dr. Kevin Folta engages with Dr. Alex Schneider, CEO and founder of CureLab, to discuss innovative approaches to cancer treatment, particularly focusing on the challenges posed by refractory cancers such as triple-negative breast cancer and platinum-resistant ovarian cancer.